Key facts
- This page summarizes Third Rock Ventures VI, L.P.'s Form 3 filing for Tango Therapeutics, Inc. (TNGX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Aug 2023, 16:15.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
The shares of common stock were acquired by the Reporting Person pursuant to a securities purchase agreement in a private placement offering of shares of the Issuer's common stock, which offering closed on August 11, 2023.
Footnote F2
These shares are directly held by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI and TRV GP VI LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
SEC remarks
Reid Huber, a partner at Third Rock Ventures, LLC, has been deputized to represent the Reporting Persons (and other funds affiliated with Third Rock Ventures, LLC that hold shares of the Issuer's stock) on the board of directors of the Issuer. By virtue of Mr. Huber's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Person may be deemed directors by deputization of the Issuer.